Cushing's disease (CD) is due to an adrenocorticotrophin (ACTH)-secreting pituitary tumour leading to excess cortisol production. Transphenoidal surgery (TSS) remains the mainstay of treatment, effective in 80% of cases. This study investigated the desmopressin (DDAVP) and corticotrophin-releasing hormone (CRH) stimulation tests as predictors of long-term outcome after TSS.
Cushing's disease (CD) is due to an adrenocorticotrophin (ACTH)-secreting pituitary tumour leading to excess cortisol production. Transphenoidal surgery (TSS) remains the mainstay of treatment, effective in 80% of cases. This study investigated the desmopressin (DDAVP) and corticotrophin-releasing hormone (CRH) stimulation tests as predictors of long-term outcome after TSS.
Patients (n ¼ 57) were followed up for at least 24 months post-TSS. During follow-up, the patients were divided into the following three groups: remission after TSS (n ¼ 24), late recurrence (n ¼ 15) and those with persistent disease after TSS (n ¼ 18). In the late recurrence group, median time to relapse was 40 months. Remission was defined clinically by the need for steroid replacement and by serum cortisol and urinary free cortisol concentrations.
The DDAVP and CRH tests were performed at six months with a 48 h interval between tests. DDAVP stimulation showed significantly higher ACTH peaks in the late recurrence group when compared to the remission group (P < 0.0001). The percentage and absolute increases in ACTH concentration were higher in the recurrence versus the remission group. Receiver-operator characteristic (ROC) analysis to detect recurrence showed a sensitivity of 93% and specificity of 82% (cut-off change in ACTH > 9 ng/L).
CRH stimulation showed no difference in baseline cortisol concentration between the remission and the recurrence groups, but the remission group demonstrated lower ACTH concentrations. The increase and peak in ACTH concentration were statistically higher in the recurrence group versus the remission group (P ¼ 0.004 and 0.001, respectively). ROC analysis to predict recurrence showed a sensitivity of 73% and specificity of 76% (cut-off change in ACTH > 37 ng/L).
The authors concluded that DDAVP stimulation confirmed its role in identifying patients at high risk of recurrence. ACTH response to CRH stimulation may provide further information when combined with the DDAVP stimulation test. A positive response to both tests revealed a positive predictive value of 100%, and a negative response to both tests had a negative predictive value of 100%.
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Distinct injury markers for the early detection and prognosis of incident acute kidney injury in critically ill adults with preserved kidney function Acute kidney injury (AKI) is common in the critically ill and is associated with a high hospital mortality rate. In this patient group, the use of biomarkers to detect AKI is hindered by the heterogeneity of injury and the effects of prevalent AKI. A single biomarker is unlikely to reflect the multiple pathways involved.
This study attempted to improve diagnostic performance by using three distinct urine markers: neutrophil gelatinase-associated lipocalin (NGAL), L-type fatty acid-binding protein (L-FABP) and cystatin C. The authors measured these markers in a large nested case-control study of critically ill patients to assess whether they improved prediction of the development of incident AKI, and subsequent dialysis and death, compared with a single marker alone.
Urine NGAL, L-FABP and cystatin C and serum creatinine were measured at study enrolment and after 48 h. AKI cases were identified (n ¼ 130), and compared to controls (n ¼ 250) without AKI, by measurement of serum creatinine on patients admitted to one of four intensive care units. Patients were followed up prospectively until hospital discharge.
Urine cystatin C did not show any difference between those with and without AKI and was not included in subsequent analysis. NGAL and L-FABP did not reliably discriminate between patients who did and did not develop AKI. Discrimination was improved when comparing those with more severe AKI with those with no injury. Using a multivariate regression model, both NGAL and L-FABP independently predicted AKI and subsequent need for dialysis. However, the sample size of patients who received dialysis was limited.
The study benefited from using a large and diverse critically ill population but the three urine biomarkers failed to reliably detect AKI in this patient group.
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